bDMARDs Quick Reference Guide



Active ingredient


Mechanism of action

Interleukin (IL) -23 inhibitor

Molecule type

IgG monoclonal antibody (humanised)

PBS listed indications

Severe chronic plaque psoriasis

Reference product (brand)


Biosimilar brands


Administration information

Mode of administration

Subcutaneous injection

Administration devices and strengths

Pre-filled syringe 100mg/mL

Instructions for patient self-administration are outlined in the CMI.

Frequency of administration

Every 12 weeks (maintenance)


Store at 2-8oC (refrigerate do not freeze).

Keep pre-filled syringes in the outer carton until time of use to protect from light.

Do not shake.

Tildrakizumab is stable for up to 30 days at 25oC. Do not return to the refrigerator.

After 30 days out of the refrigerator, the pre-filled syringe should be immediately used or discarded.

For a more comfortable injection, patients may remove the carton from the refrigerator before injecting and allow to reach room temperature (15 – 30 minutes) out of direct sunlight without removing the pre-filled syringes from the carton.

Standard dosing

100mg at weeks 0 and 4 then once every 12 weeks.

Special notes

Immunosuppression may increase risk and severity of infection. Do not use if there is a serious or untreated infection, e.g. sepsis, active TB (before completing treatment). Use caution if the person has a chronic infection or history of recurrent infections.

Tildrakizumab has the potential to reactivate latent TB (begin TB treatment before starting).
Patients with suspected latent or active TB should be treated in consultation with an Infectious Diseases physician.


Live vaccines should not be given concurrently with tildrakizumab or for at least 17 weeks after treatment.


Pharmaceutical benefits Scheme (PBS) listing. Available from [accessed 8/10/21] 

Product information. Available from [accessed 8/10/21] 

Australian Medicines Handbook 2020 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2020 July. Available from:   [accessed 12/5/21]